Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1426 clinical trials
Evaluation of the Cell Detachment Ratio on pH-responsive Chitosan as a Prognostic Factor in Lung Cancer

Biomaterial-based cell culture models have been gaining increasing attention as potential therapeutic strategies. The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be correlated with the overall survival in lung cancer patients.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Surface Landmarks and C-length as Predictors of Depth of Right IJV Catheter Insertion: A TEE-Guided Study

The primary aim of the current study is to examine the accuracy of the C-distance or surface landmarks in determining the length of central venous catheter (CVC) that is required to place the catheter tip at the mid-superior vena cava (SCV) as confirmed by transesophageal echocardiography (TEE). A secondary aim …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference

This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.

fatty liver
magnetic resonance elastography
nash
steatohepatitis
elastography
  • 0 views
  • 05 Aug, 2020
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS) (MARS)  

Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY …

  • 0 views
  • 19 Sep, 2022
  • 1 location
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS) (MARS)

Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY …

  • 0 views
  • 19 Sep, 2022
  • 2 locations
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS) (MARS)

Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY …

  • 0 views
  • 19 Sep, 2022
  • 1 location
Follow-up of Critical COVID-19 Patients

The study will follow COVID-19 patients who required intensive care after 3-6 months and one year after discharge from the ICU with functional level as well as organ function to assess recovery after COVID-19. Blood and urine will be collected for biobanking.

covid-19
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Continuous Infusion of Ketamine in Pediatric Intensive Care Unit (KISS Study)

This study, prospectively evaluate the efficacy and safety of ketamine administered in continuous infusion lasted more than 12 hours in children admitted to Pediatric Intensive Care Unit of Padova. This drug may be used as adopted as adopted as adjuvant to analgesia and sedation or as adjuvant to bronchospasm therapy. …

ketamine
delirium
pediatric
continuous infusion
analgesics
  • 0 views
  • 16 Feb, 2024
  • 1 location
Bone-biomarkers of Spinal Cord Injury Patients

Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

romosozumab
spinal cord disorder
osteoporosis
sclerostin inhibitor
spinal cord injury
  • 0 views
  • 16 Feb, 2024
  • 1 location
Acquired Syphlis by Non Sexual Contact

Syphilis is classically described as a sexually transmitted disease. As this source of contagious has been described long ago -mainly though by observation- when children presents with acquired syphilis, child abuse is always considered and must be ruled out by specialists in a careful evaluation.

  • 0 views
  • 05 Aug, 2020